Strategies to make Ramadan fasting safer in type 2 diabetics: A systematic review and network meta-analysis of randomized controlled trials and observational studies

Medicine (United States)

Volumn 95, Issue 2, 2016, Pages

  Lee, Shaun Wen Huey ^a   Lee, Jun Yang ^a   Tan, Christina San San ^b   Wong, Chee Piau ^a  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b SEGI UNIVERSITY   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN DETEMIR;

ARTICLE; CONFIDENCE INTERVAL; DIET RESTRICTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MUSLIM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RAMADAN FASTING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; ADULT; ADVERSE EFFECTS; AGED; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; ISLAM; LEISURE; MALE; MIDDLE AGED; PATIENT SAFETY; RISK ASSESSMENT;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; FEMALE; HOLIDAYS; HUMANS; HYPOGLYCEMIA; ISLAM; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84958205820     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002457     Document Type: Article

References (46)

1. The Global Religious Landscape: A Report on the Size and Distribution of the World's Major Religious Groups as of 2010 Washington, DC: Pew Research Center; 2012.
2. Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306-2311.
3. Beshyah S, Benbarka M, Sherif I. Practical management of diabetes during Ramadan fast. Libyan J Med. 2007;2:185-189.
4. Abrams KR, Gillies CL, Lambert PC. Meta-analysis of heteroge-neously reported trials assessing change from baseline. Stat Med. 2005;24:3823-3844.
5. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multi-variate meta-regression. Res Synth Methods. 2012;3:111-125.
6. Chaimani A, Higgins JPT, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e76654.
7. Weiss J. Fasting in Ramadan despite chronic diseases. Dtsch Med Wochenschr. 2009;134:29-30.
8. Katibi I, Akande A, Bojuwoye B, et al. Blood sugar control among fasting Muslims with type 2 diabetes mellitus in Ilorin. Niger J Med. 2001;10:132-134.
9. Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65:1132-1140.
10. Al-Arouj M, Hassoun AAK, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013;67:957-963.
11. Anwar A, Azmi KN, Hamidon BB, et al. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia. 2006;61:28-35.
12. Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28: 1289-1296.
13. Bakiner O, Ertorer M, Bozkirli E, et al. Repaglinide plus singledose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol. 2009;46:63-65.
14. Belkhadir J, Ghomari HE, Klöcker N, et al. Muslims with noninsulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. Br Med J. 1993;307:292-294.
15. Brady EM, Davies MJ, Gray LJ, et al. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab. 2014;16:527-536.
16. Cesur M, Corapcioglu D, Gursoy A, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract. 2006;75:141-147.
17. Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63:1446-1450.
18. Halimi S, Levy M, Huet D, et al. Experience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: insights from the VERDI study. Diabetes Ther. 2013;4:385-398.
19. Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319-326.
20. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27:1367-1374.
21. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002;58:45-53.
22. Malha LP, Taan G, Zantout MS, et al. Glycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in Ramadan. Ther Adv Endocrinol Metab. 2014;5:3-9.
23. Salti I. Diabetes and Ramadan Study Group. Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan. Diabet Med. 2009;26:1255-1261.
24. Sari R, Balci M, Akbas S, et al. The effects of diet, sulfonylurea, and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res. 2004;30:169-177.
25. Shete A, Shaikh A, Nayeem K, et al. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes. 2013;4:358-364.
26. Vasan S, Thomas N, Bharani, et al. A double-blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Int J Diabetes Dev C. 2006;26:70.
27. Akram J, De Verga V. Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group. Diabet Med. 1999;16:861-866.
28. Hui E, Bravis V, Salih S, et al. Comparison of Humalog Mix50 with human insulin Mix30 in type 2 diabetes patients during Ramadan. Int J Clin Pract. 2010;64:1095-1099.
29. Mattoo V, Milicevic Z, Malone JK, et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract. 2003;59: 137-143.
30. Mustafa HE, Hashim T, Beshyah SA, et al. The effect of ''Targeted Diabetes Education'' on glycemic control during Ramadan fasting. Ibnosina J Med BS. 2012;4:242-248.
31. Prataksitorn C, Singchungchai P. The effective of Ramadan focused education on awareness and glycemic control of diabetic Muslims (Type 2 diabets) during Ramadan fasting. Int J Public Health Res. 2014;4:405-411.
32. Susilparat P, Pattaraarchachai J, Songchitsomboon S, et al. Effectiveness of contextual education for self-management in Thai Muslims with type 2 diabetes mellitus during Ramadan. J Med Assoc Thai. 2014;97:S41-S49.
33. McEwen LN, Ibrahim M, Ali NM, et al. Impact of an individualized type 2 diabetes education program on clinical outcomes during Ramadan. Br Med J Open Diab Res Care. 2015;3:e000111.
34. Wangthong A, Cheyoe N. Effects of diabetic drug adjustment among fasting diabetic patients during the Ramadan period in Nongjik District, Pattani Province. J Health Syst Res. 2008;2:130-135.
35. Shehadeh N, Maor Y. The Ramadan Study G. Effect of a new insulin treatment regimen on glycaemic control and quality of life of Muslim patients with type 2 diabetes mellitus during Ramadan fast: an open label, controlled, multicentre, cluster randomised study. Int J Clin Pract. 2015;69:1281-1288.
36. Norouzy A, Mohajeri S, Shakeri S, et al. Effect of Ramadan fasting on glycemic control in patients with type 2 diabetes. J Endocrinol Invest. 2012;35:766-771.
37. Lee JY, Lee SWH, Nasir NH, et al. Diabetes telemonitoring reduces the risk of hypoglycaemia during Ramadan: a pilot randomized controlled study. Diabetic Med. 2015;32:1658-1661.
38. Al-Arouj M, Bouguerra R, Buse J, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care. 2005;28:2305-2311.
39. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1-52.
40. Ibrahim M, Abu Al Magd M, Annabi FA, et al. Recommendations for management of diabetes during Ramadan: update 2015. Br Med J Open Diabetes Res Care. 2015;3:e000108.
41. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Br Med J. 2012;344:e1369.
42. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27:528-542.
43. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352: 837-853.
44. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
45. Gary TL, Genkinger JM, Guallar E, et al. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ. 2003;29:488-501.
46. Gray LJ, Dales J, Brady EM, et al. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis. Diabetes Obes Metab. 2015;17: 639-648.